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ARTICLE
Obesity and disease severity magnify disturbed
microbiome-immune interactions in asthma
patients
David Michalovich 1, Noelia Rodriguez-Perez2, Sylwia Smolinska 3,4, Michal Pirozynski 5, David Mayhew6,
Sorif Uddin1,7, Stephanie Van Horn 8, Milena Sokolowska2,9, Can Altunbulakli2, Andrzej Eljaszewicz 2,9,10,
Benoit Pugin2, Weronika Barcik2, Magdalena Kurnik-Lucka11, Ken A. Saunders1, Karen D. Simpson1,
Peter Schmid-Grendelmeier9,12, Ruth Ferstl2,9, Remo Frei2,9, Noriane Sievi13, Malcolm Kohler13,
Pawel Gajdanowicz 3,4, Katrine B. Graversen 14, Katrine Lindholm Bøgh 14, Marek Jutel3,4,
James R. Brown 6, Cezmi A. Akdis2,9, Edith M. Hessel 1,16 & Liam O’Mahony2,15,16*
In order to improve targeted therapeutic approaches for asthma patients, insights into the
molecular mechanisms that differentially contribute to disease phenotypes, such as obese
asthmatics or severe asthmatics, are required. Here we report immunological and micro-
biome alterations in obese asthmatics (n= 50, mean age= 45), non-obese asthmatics (n=
53, mean age= 40), obese non-asthmatics (n= 51, mean age= 44) and their healthy
counterparts (n= 48, mean age= 39). Obesity is associated with elevated proinﬂammatory
signatures, which are enhanced in the presence of asthma. Similarly, obesity or asthma
induced changes in the composition of the microbiota, while an additive effect is observed in
obese asthma patients. Asthma disease severity is negatively correlated with fecal Akker-
mansia muciniphila levels. Administration of A. muciniphila to murine models signiﬁcantly
reduces airway hyper-reactivity and airway inﬂammation. Changes in immunological pro-
cesses and microbiota composition are accentuated in obese asthma patients due to the
additive effects of both disease states, while A. muciniphila may play a non-redundant role in
patients with a severe asthma phenotype.
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Changes in lifestyle, diet, weight, environment and micro-biome have all been associated with an increased risk andseverity of chronic inﬂammatory disorders such as aller-
gies and asthma1,2. However, the complex interactions between
these factors and host immunoregulatory processes are still
poorly understood at a mechanistic level in humans. In particular,
it is unclear if changes in microbiota composition contribute to
disease pathology or if these changes reﬂect altered immune
reactivity within host tissues3. The microbiota contributes sig-
niﬁcantly to host health via multiple mechanisms4,5. Both the
composition and metabolic activity of microbiota have profound
effects on proinﬂammatory activity and the induction of immune
effector functions or tolerance within mucosal tissues6–8. A
diverse microbiota contributes to a balanced homeostatic
immunological state, while microbial dysbiosis has been asso-
ciated with many inﬂammatory diseases including asthma and
obesity9–11.
Asthma is characterized by recurrent and reversible airﬂow
obstruction with airway inﬂammation central to its pathogen-
esis12. Several different molecular mechanisms can lead to similar
clinical outcomes, which has led to the concept of linking asthma
endotypes (an asthma subtype deﬁned by a distinct pathophy-
siological mechanism) with asthma phenotypes13. However, to
fully understand the complex interactions between innate and
adaptive immune cells in different endotypes, additional factors
such as the microbiome, nutrition and host metabolic activity
need to be considered so that therapeutic options can be identi-
ﬁed and dysregulated mechanisms appropriately targeted.
Since 1980, the number of obese individuals has doubled in
more than 70 countries14. Correspondingly, the number of obese
patients with asthma has also risen dramatically15. Obesity has
been found to be a distinguishing variable for clustering and
classifying asthma subtypes (e.g., enriched in women with adult
onset) and the obese asthmatic is more likely to become corti-
costeroid resistant, has a higher risk of being hospitalized and
more frequently presents with severe disease16–21. Severe asthma
is deﬁned as asthma that requires treatment with high‐dose
inhaled corticosteroids combined with a second controller and/or
systemic corticosteroids to maintain control or, asthma that
remains uncontrolled despite this therapy22. However, both obese
and non-obese asthma patients can present with severe disease
and it is currently unknown if similar or divergent factors, such as
the microbiome, might contribute to asthma severity independent
of obesity23,24.
In this study, our aim is to comprehensively characterize the
immunological and microbiota changes that occur in obese
asthma patients and to determine if these changes are related to
asthma, to obesity, or both. In addition, we determine if changes
in the microbiota associated with asthma severity are shared
between obese and non-obese asthma patients. We describe here
substantial additive effects of obesity and asthma on host
immunological responses and the microbiota. In addition, both
obese and non-obese asthma patients with severe disease have
reduced fecal levels of Akkermansia muciniphila, which may have
a causal relationship as suggested by murine models of acute and
chronic airway inﬂammation.
Results
Systemic inﬂammation is enhanced by obesity and asthma.
Patient demographic details and comorbidities are detailed in
Table 1 and Supplementary Table 1, respectively. Inﬂammatory
markers were measured in serum of obese asthmatics (n= 50),
non-obese asthmatics (n= 52), obese non-asthmatics (n= 50),
and their non-obese non-asthmatic healthy counterparts (n=
47). The liver acute phase proteins C-reactive protein (CRP),
serum amyloid A (SAA) and ﬁbrinogen were signiﬁcantly ele-
vated in the serum of obese non-asthma and obese asthma
patients (Fig. 1a and Supplementary Fig. 1). Similarly, proin-
ﬂammatory cytokines and chemokines were signiﬁcantly elevated
in the serum of both obese patient groups. Gene expression
analysis of whole blood identiﬁed differentially expressed genes
(DEGs) in obese asthmatics (n= 50), non-obese asthmatics (n=
53), obese non-asthmatics (n= 51) relative to healthy volunteers
(n= 48, Supplementary Fig. 2). Signiﬁcant enrichments in
ontologies related to inﬂammatory and innate immune responses
(Fig. 1b) were accentuated in obese asthmatics (n= 50), sug-
gesting an additive effect between obesity and asthma.
Airway inﬂammation is inﬂuenced by obesity and asthma. We
obtained bronchoalveolar lavage (BAL) ﬂuid and bronchial
biopsies from obese asthmatics (n= 10), non-obese asthmatics
(n= 12), obese non-asthmatics (n= 11) and their non-obese
non-asthmatic healthy counterparts (n= 8). Acute phase pro-
teins, ICAM-1 and VCAM-1 levels were elevated in BALs from
obese patients (Fig. 2a and Supplementary Fig. 3). Non-obese
asthma patients (n= 12) had the highest levels of chemokines
within BAL. However, BAL IL-5 levels were signiﬁcantly elevated
for both obese (n= 10) and non-obese asthma (n= 12) patients.
The total number of inﬂammatory cells (including eosinophils,
neutrophils and lymphocytes) in BAL cytospins was signiﬁcantly
different between the groups (p= 0.042, ANOVA). However,
while elevated eosinophils, neutrophils, and lymphocytes were
observed in speciﬁc obese non-asthma, non-obese asthma and
obese asthma patients, none of the inﬂammatory cell types alone
were statistically signiﬁcantly different between the groups
(Fig. 2b). The presence of eosinophils and neutrophils was con-
ﬁrmed by H&E staining in available biopsies (Supplementary
Fig. 4).
Transcriptomic analysis of bronchial biopsies revealed a
number of genes and related pathways that were differentially
expressed in obese and asthmatic individuals. The top ten most
signiﬁcant gene ontology pathway enrichments for each group are
illustrated in Supplementary Fig. 5a, while expanded heatmaps of
immunologically relevant DEGs are illustrated in Supplementary
Fig. 5b. Asthma-related gene ontology pathways were enriched in
both non-obese asthmatics (n= 12) and obese asthmatics (n=
10), but not obese non-asthmatics (n= 11), compared to non-
obese non-asthmatic controls (n= 8, Fig. 2c). Both obese groups
displayed signiﬁcant enrichments in pathways relating to airway
remodeling and inﬂammatory responses (Fig. 2c). In BALs, the
top ten most signiﬁcant gene ontology pathway enrichments for
each group are illustrated in Supplementary Fig. 6a, while
expanded heatmaps of immunologically relevant DEGs are
illustrated in Supplementary Fig. 6b. Asthma-related gene
ontology pathway enrichments were evident in BALs from non-
obese asthmatics, while enrichments in gamma-secretase proteo-
lytic targets, epithelial-to-mesenchymal transition and WNT
signaling were observed in both obese groups (Fig. 2d).
Obesity and asthma inﬂuence microbiome composition. To
investigate the relationship between obesity, asthma and the
microbiome, we performed 16S rRNA proﬁling of samples from
the lower gastrointestinal tract (gut, n= 202), upper gastro-
intestinal tract (oral, n= 41), lower respiratory tract (BAL, n=
41) and upper respiratory tract (nasal, n= 41). The composition
of the microbiota showed signiﬁcant differences based on body
site (Fig. 3a). Speciﬁc differences at the genus taxonomic level
were observed between groups for the lower respiratory tract
(BALs, Fig. 3b), upper respiratory tract (nasal, Fig. 3c), upper
gastrointestinal tract (oral, Fig. 3d) and lower gastrointestinal
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tract (fecal, Fig. 3e), after correcting for known covariates, age and
gender (Supplementary Table 2). Interestingly, multiple differ-
ences were shared between the obese groups, or the asthma
groups, especially within the BAL samples, suggesting that obesity
and asthma have an additive effect on the microbiome alterations
associated with asthma in obese individuals. Of note, the relative
abundance of Dehalobacterium was increased for all asthma
patients, independent of BMI. A random-forest classiﬁer model of
Table 1 Patient demographics.
Healthy controls Non-obese asthma Obese non-asthma Obese asthma p-value
n 48 53 51 50
Age (S.D.) 39.4 (11.9) 39.5 (11.3) 44.4 (13.5) 44.6 (11.6) 0.078
BMI (S.D.) 22.2 (1.4) 22.9 (1.5) 35.6 (4.6) 34.6 (5.1) <0.001
Male/female 19/29 22/31 18/33 17/33 0.817
Smoker (%) 18 (38) 8 (15) 20 (40) 9 (18) 0.011
Alcohol U/week (S.D.) 2.3 (2.2) 2.5 (3.5) 1.8 (2.4) 1.4 (2.0) 0.141
FEV1% (S.D.) – 81.7 (15.5) – 79.8 (17.3) 0.619
Allergy (%) – 40 (75) – 36 (72) 0.823
Daily ICS (%) – 38 (72) – 40 (80) 0.365
Daily ICS dose (S.D.)a – 678 (585) – 946 (710) 0.054
Oral steroids (%) – 2 (4) – 8 (16) 0.048
SABA (%) – 22 (42) – 26 (52) 0.327
LABA (%) – 33 (62) – 31 (62) 1.000
Daily LABA dose (S.D.)b – 62 (56) – 86 (78) 0.098
Anti-histamines (%) – 32 (60) – 30 (60) 1.000
Leukotriene receptor antagonist (%) – 27 (51) – 27 (54) 0.844
Daytime asthma symptoms >2 times(%) – 10 (19) – 18 (36) 0.076
Exercise/activity limited due to asthma(%) – 18 (34) – 25 (50) 0.113
Waking at night due to asthma symptoms(%) – 12 (23) – 21 (42) 0.056
Use of rescue medications >2 times(%) – 14 (26) – 12 (24) 0.824
aDose of inhaled glucocorticosteroids calculated as a budesonide equivalent microgram/day
bDose of LABA calculated as a salmeterol equivalent microgram/day
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Fig. 1 Blood inﬂammatory proﬁles. a Fold change of cytokine levels in serum for obese non-asthma (n= 50), obese asthma (n= 50) and non-obese
asthma (n= 52) patients relative to the non-obese non-asthmatic group (n= 47) are illustrated. All comparisons with a P < 0.05 (ANOVA with post hoc
Tukey-kramer test) are labeled with asterisks. b Gene ontology pathway enrichments in whole blood for obese non-asthma (n= 51), obese asthma (n=
50) and non-obese asthma (n= 53) patients relative to the non-obese non-asthmatic group (n= 48) are illustrated using both the proportion of the
pathway or ontology gene set that overlapped with the differentially expressed genes in that comparison and the FDR-corrected p-values as a label next to
the bar. Source data are provided as a Source Data ﬁle.
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Fig. 2 Lung inﬂammatory proﬁles. a Fold change of cytokine levels in bronchoalveolar lavages (BALs) for obese non-asthma (n= 11), obese asthma (n=
10) and non-obese asthma (n= 12) patients relative to the non-obese non-asthmatic group (n= 7) are illustrated. All comparisons with a P < 0.05
(ANOVA with post hoc Tukey-kramer test) are labeled with asterisks. b Total inﬂammatory cell numbers and differential cell counts in BAL cytospins are
illustrated (mean+/− standard error). Gene ontology enrichments in asthma-related pathways or airway remodeling/inﬂammation-related pathways in
c lung biopsy and d BALs for each group (Non-obese asthma (n= 12); Obese non-asthma (n= 11); Obese asthma (n= 10)) compared to non-obese and
non-asthma volunteers (n= 8), are illustrated using both the proportion of the pathway or ontology gene set that overlapped with the differentially
expressed genes in that comparison and the FDR-corrected p-values as a label next to the bar. Source data are provided as a Source Data ﬁle.
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the fecal microbiota had a reasonable ability to distinguish obesity
(AUC= 0.76), but little predictive value for asthma (AUC=
0.53). No signiﬁcant differences were observed for alpha diversity
measures between the groups, except for the obese asthmatics
who had a signiﬁcantly increased Shannon diversity within the
nose (Supplementary Fig. 7).
Microbiome correlates with markers of inﬂammation. Within
the gut microbiota, three distinct bacterial enterotypes were evi-
dent, as already described by others25. A Bacteroides-dominated
enterotype (E1, Bacteroides:Prevotella ratio > 2.0), a Prevotella-
dominated enterotype (E2, Bacteroides: Prevotella ratio < 0.50)
and a mixed enterotype (Emix) were observed (Fig. 4a). Patients
with a Prevotella-rich gut enterotype (E2, n= 39) displayed
increased serum levels of the chemokines CCL22, CCL13, CCL17,
and CXCL10 compared to individuals with an E1 (n= 116) or
Emix (n= 37) enterotype (Fig. 4b). In addition, several serum
biomarkers were signiﬁcantly correlated (p < 0.01, Pearson’s test)
with the levels of speciﬁc gut microbes in both obese (Supple-
mentary Fig. 8a) and asthma patients (Supplementary Fig. 8b).
Among BAL samples (n= 40), signiﬁcant correlations were
observed between inﬂammatory cell numbers and microbiome
composition (Supplementary Table 3). Of note, increased
eosinophils in asthma patients, regardless of their BMI, was
associated with an increased relative abundance of the genera
Rothia, Dorea, Lautropia, and Haemophilus. We explored two
major variables, smoking status and inhaled corticosteroids, for
their effect on oral, nasal, and BAL microbiome, and observed no
statistically signiﬁcant differences between these groups in the
microbiome composition at each airway site (PERMANOVA p >
0.05 for each). In contrast, signiﬁcant associations (p < 0.01,
Pearson’s test) between BAL cytokine levels with individual
microbial genera were observed in obese patients (Supplementary
Fig. 9a) and asthma patients (Supplementary Fig. 9b). In addition,
focusing only on the taxa that were shown to be signiﬁcantly
decreased within the asthma BALs (Fig. 3b), their combined
relative abundance inversely correlated with BAL IL-5, IFN-γ,
and IL-15 levels (n= 40, Fig. 4c).
Akkermansia muciniphila decreases in severe asthma patients.
In addition to the effects of obesity on the gut microbiota of
asthma patients, we evaluated if asthma disease severity could
also inﬂuence the composition of the gut microbiota. In patients
with severe asthma (n= 41), a signiﬁcant reduction in the family
Verrucomicrobiaceae was observed, compared to patients with
mild/moderate asthma (n= 53, Fig. 5a). The most common
species within this family is Akkermansia muciniphila, which
showed a signiﬁcant decrease (p= 0.0041) in its relative abun-
dance in severe asthma patients (Supplementary Fig. 10). The
reduced level of A. muciniphila was speciﬁcally associated with
severe asthma as the relative abundance of A. muciniphila was not
signiﬁcantly different between the asthma or obese groups (non-
obese non-asthmatic 0.046+/− 0.082, non-obese asthmatics
0.035+/− 0.069, obese non-asthmatics 0.026+/− 0.028, obese
asthmatics 0.046+/− 0.076, mean plus/minus (+/−) standard
deviation, p > 0.05 ANOVA). Both obese and non-obese asth-
matics with severe disease (n= 22 and n= 19, respectively)
showed a signiﬁcant decrease in A. muciniphila compared to
obese and non-obese patients with mild/moderate asthma (n= 23
and n= 30, respectively, Fig. 5b). Using qPCR primers speciﬁc to
A. muciniphila, we observed a strong concordance with the
relative abundance data (rho= 0.762) and we conﬁrmed the
reduced levels in Akkermansia associated with severe disease
(Fig. 5c). In asthma patients, we also observed a negative corre-
lation between A. muciniphila and circulating CRP levels
(Fig. 5d). These data suggest that lower levels of A. muciniphila
are associated with a higher risk of severe asthma symptoms.
A. muciniphila reduces airway inﬂammation in animal models.
In order to determine if any of the microbial changes described
above might play a causal role in inﬂuencing respiratory
inﬂammation, we selected A. muciniphila to test further in
murine models of allergen-induced respiratory airway disease.
Oral administration of A. muciniphila induced a marked reduc-
tion in BAL eosinophil numbers in female animals sensitized and
challenged with ovalbumin (OVA), compared to animals that
received OVA alone (n= 5 mice per group, Fig. 6c). In addition,
IL-4 and IL-5 secretion from OVA-stimulated isolated lung cells
was reduced in animals treated with A. muciniphila (Fig. 6c).
Heat killed A. muciniphila or cell free supernatants from A.
muciniphila cultures did not reduce OVA-induced eosinophilia
or cytokine levels (Fig. 6c). A. muciniphila administration, but not
heat killed A. muciniphila or its supernatant, was associated with
an altered lymphocyte proﬁle within lung tissue as the percentage
of IL-4 and IFN-γ positive CD4 T cells were reduced, while
IL-10+ Foxp3+ double positive lymphocytes were increased
(n= 5 mice per group, Fig. 6d and Supplementary Fig. 11). A.
muciniphila was equally effective in reducing BAL inﬂammatory
cell numbers in male mice (n= 6 per group, Fig. 6e). Airway
hyper-reactivity in response to methacholine was signiﬁcantly
reduced in animals administered A. muciniphila (n= 8–9 mice
per group, Fig. 6f). Oral administration of A. muciniphila sig-
niﬁcantly reduced the number of BAL inﬂammatory cells in the
acute house dust mite (HDM) extract challenge model (n= 7–8
mice per group, Fig. 6g). A. muciniphila was equally effective in
reducing BAL inﬂammatory cell numbers in MyD88−/− animals
(n= 5 mice per group, Fig. 6h). A. muciniphila levels in fecal
samples increased 1000–10,000 fold in exposed mice, while A.
muciniphila was not detected in the BALs from exposed animals
(n= 3 mice per group at each time point, Fig. 6i).
The inﬂuence of A. muciniphila on airway inﬂammation was
also assessed in a chronic model of HDM exposure, in which
persistent airway inﬂammation was initiated prior to adminis-
tration of A. muciniphila. Administration of A. muciniphila
reduced the number of all innate and adaptive cell types
examined within the BAL, suggesting that A. muciniphila
accelerated the resolution of airway inﬂammation following
cessation of HDM exposure (n= 6 mice per group, Fig. 7b and
Supplementary Fig. 12). In additional groups of animals, mice
chronically exposed to HDM were allowed to recover in the
absence of HDM and were then re-challenged with a single high
dose of HDM extract. A signiﬁcant inﬂux of eosinophils was
observed in the BAL within 24 h post re-challenge (n= 6–8 mice
per group at each time point, Fig. 7d). However, re-challenged
animals that received A. muciniphila during the resolution phase
displayed a signiﬁcantly reduced eosinophil response (Fig. 7d). Of
note was the reduction in inﬁltration of a sub-set of eosinophils
expressing high levels of Sialic acid-binding immunoglobulin-
type lectin-F (Siglec−Fhi) (n= 6 mice per group, Fig. 7e).
Representative dot-plots illustrating the presence of Siglec−Fhi
eosinophils in the lung are illustrated in Fig. 7f.
Discussion
In this study we describe immunological and microbiome
alterations that are associated with obesity and asthma. In addi-
tion, we clearly identify an obese asthma phenotype that shares
immunological and microbiome features of both obesity and
asthma. Furthermore, we discovered that asthma severity was
associated with reduced levels of A. muciniphila in the gut, which
may be clinically relevant as this bacterium was protective in
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multiple murine models of both acute and chronic respiratory
airway disease.
The combination of obesity and asthma had signiﬁcant
effects on host inﬂammatory and transcriptomic responses.
This was clearly observed in the peripheral blood tran-
scriptome, where enrichments in ontologies related to inﬂam-
matory and innate immune responses were accentuated in
obese asthmatics, suggesting an additive effect between obesity
and asthma. Within BALs and lung biopsies, non-obese asthma
patients showed enrichments for TH2 and asthma-related
ontologies, while obese non-asthma patients showed enrich-
ments for tissue-remodeling-related and inﬂammation-related
ontologies. Obese asthmatics displayed enrichments in tissue
remodeling-related, inﬂammation-related and TH2-related
ontologies. However, the quantitative additive effect observed
for speciﬁc ontology enrichments in peripheral blood was not
observed for BALs or lung biopsies, rather the obese asthmatic
displayed qualitative additive effects in gene ontologies repre-
senting both asthma and obesity signatures within the lung. This
difference between systemic versus pulmonary-speciﬁc responses
may reﬂect the contribution of multiple organs (e.g., liver and
adipose tissue) to systemic inﬂammatory gene responses26.
Previous studies have demonstrated that obesity is associated
with an altered gut microbiota25,27,28. Our data extends these
ﬁndings in showing that the composition of the microbiota
changes in both the obese and asthma states relative to healthy
individuals, not only in gut and lung, but also in the nose and
mouth. This suggests that the microbiota can be altered at sites
distant to the diseased organ, perhaps due to the inﬂuence of diet,
inﬂammation or medications. Certain microbiota changes in the
obese asthmatic were shared by obese individuals or by patients
with non-obese asthma. Thus, the additive effect of having
asthma and being obese exaggerates the microbial changes pre-
sent in these patients. In obese asthmatics, atopic status is likely to
also play a role in better phenotyping this patient group, parti-
cularly their response to treatments such as weight loss. However,
the majority of obese asthmatics described in this cohort are
atopic and therefore it was not possible to further separate
microbiome-host effects associated with atopic status in obese
asthmatics. One additional ﬁnding is the identiﬁcation of
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Dehalobacterium in obese and non-obese asthma patients.
Dehalobacterium is a strictly anaerobic dichloromethane-
degrading bacterium29,30. Dichloromethane present in the
environment is the result of industrial emissions and increased
levels of Dehalobacterium may therefore indirectly indicate
greater exposure to solvents containing this compound. However,
further work is required to determine if an increase in this
organism has any inﬂuence on host immune responses.
Signiﬁcant associations were observed between the compo-
sition of the microbiota and host inﬂammatory responses,
reinforcing the hypothesis that there is a close relationship
between immune regulatory mechanisms and the microbes that
reside within us. For example, the highest serum chemokine
levels were observed in those with a Prevotella-dominated gut
microbiota. This association was observed regardless of obesity
or asthma status, suggesting a causal relationship. In addition,
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the close relationship between BAL microbiota composition
and GM-CSF levels in asthma patients is intriguing as GM-CSF
has been shown in murine models to inﬂuence lung TH2-
associated sensitization31.
A. muciniphila is a mucin-degrading organism and has been
previously associated with protective effects in obesity
models32,33. However, we found that A. muciniphila was reduced
in asthma patients with severe disease, regardless of their BMI. In
addition, the experimental models were performed using lean
mice, suggesting an inﬂuence on lung inﬂammatory responses
independent of its effects on obesity-associated inﬂammation.
While all inﬂammatory cells were reduced in the murine inﬂamed
lungs, a surprising ﬁnding was the signiﬁcant reduction in eosi-
nophils expressing high levels of Siglec F. These eosinophils are
IL-5-dependent and have been shown to facilitate skewing
towards a TH2 response34. Thus, the inhibitory effect of A.
muciniphila on this eosinophil population may have clinical
relevance given the established relationship between IL-5 levels,
eosinophils and asthma exacerbations35. The A. muciniphila
mechanism of action is not MyD88-dependent, but may involve
other pattern recognition receptors that are MyD88 independent
or previously described mechanisms such as improvement of gut
barrier integrity or release of metabolites such as nicotinamide
that can have systemic effects36,37. The increase in IL-10+Foxp3+
lymphocytes may also mediate anti-inﬂammatory effects within
the lung and A. muciniphila administration has previously been
shown to increase Tregs in other murine models38. In addition,
heat killed A. muciniphila was not effective suggesting that either
heat sensitive factors or viable bacteria are required for this
protective effect and any metabolites secreted in vitro were not
sufﬁcient to reduce airway inﬂammation, at least for the con-
centrations tested.
An interesting ﬁnding of our study is that obese non-asthmatic
patients show inﬂammatory changes within the lung. In addition,
it is not only the gut microbiota, but also the microbiota of the
mouth, nose, and lung that are altered in obese non-asthmatics.
Obese individuals have a higher risk of developing asthma
compared to lean individuals15 and these immune and micro-
biome changes may play a part in the increased susceptibility of
obese individuals in the development of asthma. Indeed, some of
these changes may represent pre-asthma features39. For example,
elevated BAL ICAM-1 and VCAM-1 levels in obese individuals
are suggestive of signiﬁcant vascular injury within the lung, while
the increased level of Moraxella may be clinically relevant and
should be investigated further40.
In conclusion, the microbiome and host immune responses are
intimately connected at multiple body sites and can be inﬂuenced
by obesity, asthma and asthma disease severity. The presence of
two diseases, obesity and asthma, are additive and contribute to
exaggerated inﬂammatory and microbiota changes, suggesting
that there’s a need to address obesity during asthma management.
While the obese asthma patient obviously needs to be treated
differently than a non-obese asthma patient, severe asthma may
beneﬁt from similar microbiota interventions (i.e., A. mucini-
phila), regardless of BMI. However, many of the other changes in
microbiome composition that we identiﬁed in this study may also
be biologically relevant and will need to be investigated in future
studies for their relative contributions to the stratiﬁcation and
selection of patients for speciﬁc therapies.
Methods
Patient groups. A total of 202 volunteers were recruited for this study—obese
asthma (n= 50), obese non-asthma (n= 51), non-obese asthma (n= 53), and non-
obese non-asthma healthy controls (n= 48). Asthma patients had a physician
diagnosis of asthma. Severe asthma was deﬁned according to the American
Thoracic Society (ATS) Workshop on Refractory Asthma 2000 report and by the
2013 European Respiratory Society (ERS)/ATS guidelines22,41. Obesity was deﬁned
as having a body mass index (BMI) greater than 30 kg/m2. Non-obese individuals
had a BMI of 20–25 kg/m2. All relevant ethical regulations for work with human
participants were complied with, and informed consent was obtained from all
participants. The human biological samples were sourced ethically and their
research use was in accordance with the terms of the informed consents. Patients
were recruited under informed consent at two centers, ALL-MED Medical
Research Institute, Wroclaw, Poland and the Pulmonary Division, University
Hospital of Zurich, Switzerland. Ethical approval was granted at both sites from the
local ethical committee for all study procedures (KEK-ZH-Nr. 2012–0443—Kan-
tonale Ethik-Kommission Zürich; KB-70/2013 and KB-567/2014—Bioethical
Committee, Wroclaw Medical University). Patient demographic details and
comorbidities are detailed in Table 1 and Supplementary Table 1, respectively.
Measurement of inﬂammatory mediators and cells. Serum was obtained by
allowing blood collection tubes (with no anti-coagulant) to rest at room tem-
perature for 1 h and then tubes were centrifuged at 800×g for 10 min. Serum was
removed, aliquoted in 500 μl quantities and stored at −80 °C for later analysis. BAL
was obtained and ﬁltered through a 70 μm ﬁlter into sterile tubes. Aliquots of 500 μl
were stored at −80 °C for later analysis. BAL cells were centrifuged onto slides and
following air drying were stained using the Diff-Quik stain or remained unstained.
Fixed slides were stored at −20 °C and differential cell counts were performed by
two independent histopathologists. All soluble mediators were measured using the
mesoscale discovery platform (MSD) kits according to manufacturer’s instructions.
Data were analyzed using one-way ANOVA (correcting for gender) and Tukey’s
correction.
Gene expression analysis. Peripheral blood was collected in Paxgene tubes and
immediately frozen at −80 °C until later analysis. Total mRNA was extracted from
peripheral blood using Qiagen RNeasy kit (Qiagen, Valencia, CA) and quantiﬁed
by NanoDrop (Thermo Fisher Scientiﬁc, Waltham, MA). RNA integrity was
conﬁrmed using the Agilent 2100 BioAnalyzer (Agilent, Palo Alto, CA). Samples
were normalized to the lowest concentration sample, and cDNA was made using
Superscript Vilo cDNA synthesis Master Mix (Invitrogen Life Technologies, Grand
Island, NY). The cDNA samples were then labeled with biotin with the FL-Ovation
cDNA Biotin Module V2 and hybridized to a Human Genome U133 Plus 2.0 Array
using a Genechip Hybridization Kit. The microarray chips were washed and
stained using a Genechip Hybridization Wash and Stain Kit and then scanned
using a Genechip Scanner. All reagents and readers were used according to the
manufacturer’s instructions (Affymetrix, Santa Clara, CA).
The microarray gene expression data were analyzed using ArrayStudio 7.0
(OmicSoft, Cary, NC). Data from.CEL ﬁles from Human Genome U133 Plus 2.0
Fig. 6 A. muciniphila protects against airway inﬂammation in acute murine models. The timings for allergen and bacterial administration in the a acute
ovalbumin (OVA) and b acute house dust mite (HDM) models are illustrated. c Treatment with viable A. muciniphila cells (OVA+Akk), but not heat killed
(Akk HT) A. muciniphila or A. muciniphila ﬁltered culture supernatant (Akk SN) reduces BAL eosinophil numbers and ex vivo allergen stimulated IL-4 and IL-
5 secretion in the ovalbumin (OVA) model (n= 5 mice per group). d The proportion of CD3+CD4+ T cells from lung tissue homogenates that were IL-4+
or IFN-γ+ were reduced, while the IL-10+Foxp3+ T cells increased, only in animals exposed to viable A. muciniphila (n= 5 mice per group). e A reduction in
BAL inﬂammatory cells was also observed for male mice (n= 6 mice per group). The box plot shows median and whiskers represent 10–90 percentiles.
f Airway hyper-responsiveness induced by increasing doses of methacholine were signiﬁcantly less (2way ANOVA) in mice administered A. muciniphila by
oral gavage (n= 8), compared to control animals administered a placebo gavage (n= 9). Oral administration of A. muciniphila signiﬁcantly reduced the
number of BAL inﬂammatory cells in the acute house dust mite (HDM) challenge model in g wild-type (n= 7 mice per group) and h MyD88−/− animals
(n= 5 mice per group). i A. muciniphila fecal, but not BAL, levels substantially increase in mice administered the bacterium, as measured by qPCR (n= 3 per
group per time point). Cell number was estimated using a standard curve of known numbers of bacteria. Unless otherwise indicated, statistical signiﬁcance
for two group comparisons were estimated using Mann-Whitney tests, while mean+/− SE are illustrated in each dot-plot and bar charts. Source data are
provided as a Source Data ﬁle.
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Fig. 7 A. muciniphila protects against airway inﬂammation in a chronic HDM murine model. a The timings for allergen and bacterial administration in the
chronic HDM model assessing effects on disease resolution are illustrated. b Administration of A. muciniphila (HDM+Akk) reduced the number of
eosinophils (CD45+CD11c−CD11b+MCHIIloCD24+Siglec−F+), neutrophils (CD45+CD11c-CD11b+MHCIIloCD24+Ly6-G+), monocytes (CD45+CD11c-
CD11b+CD24loMHCIIloCD64loLy6-C+), CD8 T cells (CD45+TCRβ+CD8+), B cells (CD45+CD19+), NK cells (CD45+CD49b+), and CD4 T cell subsets
(CD45+TCRβ+CD4+CD44+CD62L−CD183+/−CD196+/−) following chronic exposure to HDM (n= 6 per group). c The timings for allergen and bacterial
administration in the chronic HDM model assessing effects on high dose allergen challenge following disease resolution are illustrated. d HDM re-
challenged animals that received A. muciniphila during the resolution phase displayed a reduced eosinophil response at 24 h (n= 5 mice HDM group, n= 8
mice HDM+Akk group) and 7 days (n= 6 mice HDM group, n= 6 mice HDM+Akk group) following HDM rechallenge, e especially for the Sialic acid-
binding immunoglobulin-type lectin-F high (Siglec-Fhi) eosinophils (n= 6 per group). f Representative dot-plots illustrating the presence of Siglec-Fhi
eosinophils in the lung. Statistical signiﬁcance for two group comparisons were estimated using Mann-Whitney tests and results are shown as mean+/−
SE. Source data are provided as a Source Data ﬁle.
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Affymetrix chips were normalized using robust multiarray averaging and scaled to
a mean target intensity of 150.
BAL cells and bronchial biopsies were immediately placed in RNAlater and
stored frozen until RNA extraction was performed. Total RNA from BAL cells and
bronchial biopsies was extracted using the RNeasy Mini kit (Qiagen) and RNA
integrity was conﬁrmed using the Agilent 2100 BioAnalyzer (Agilent, Palo Alto,
CA). Samples were required to have a RIN of at least 7.0. Sequencing libraries were
prepared from RNA from each sample using the Illumina TruSeq Stranded RNA
HT sample preparation kit with RiboZeroTMGold. Libraries were barcoded and
then sequenced using an Illumina HiSeq 2000 with 51 bp paired-end reads for
targeted coverage of 50 million paired reads per sample. Quality control and
trimming of the unaligned FASTQ ﬁles was performed using the FASTX-Toolkit
(version 0.0.14). Read pairs for each biological replicate were aligned to the human
genome version hg38 using STAR (version 2.3.0e_r291) with a STAR index
using the default parameters. Samtools (version 0.1.18) was used to convert the
aligned SAM ﬁles to BAM ﬁles42,43. Read counts were determined using HTSeq
(version 0.6.0) using the htseq-count command with the default parameters
(–m union –r pos –s reverse) to deﬁne gene-levels counts from the Ensembl v85
annotated.gtf ﬁle44.
Microbiota analysis. Fecal samples were collected by volunteers at their home,
immediately chilled using ice-packs and delivered to the lab within 4 h. Upon
receipt in the lab, fecal samples were separated into 1 g aliquots and stored at
−80 °C until analysis. Pre-procedure bronchoscope wash ﬂuid (10 ml), BAL (10
ml), and mouth wash ﬂuid (2 ml) were centrifuged at high speed (22,500×g) for 30
min (Hermle Z 231M microcentrifuge; Hermle Labortechnik GmbH, Wehingen,
Germany) in dolphin-nosed eppendorf tubes and the pellets stored at −80 °C until
the time of DNA extraction. Nasal swabs of the middle meatus were stored in
preservative (Norgen Biotek, Thorold, ON) and immediately frozen. DNA was
isolated using PSP Spin Stool DNA Plus Kit (Cat#10381102, Invitek, Berlin, Ger-
many) according to the manufacturer’s instructions. Each DNA sample was
quantiﬁed by spectrophotometry. PCR ampliﬁcation of the 16S rRNA V4 region
was conducted with primers, 515f (5’-GTGCCAGCMGCCGCGGTAA-3’) and
806r (5’-GGACTACHVGGGTWTCTAAT-3’) including the Illumina sequencing
adapters and a 12 bp error-correcting Golay barcode sequence45,46. Each 50 µl PCR
reaction contained 100 ng of genomic DNA, 2× Phusion High-Fidelity PCR Master
Mix with HF Buffer (Cat# M0531L, New England Biolabs, Inc., Ipswich, MA), and
0.2 µM of each primer (Integrated DNA Technologies, Coralville, IA). PCR was
performed on an ABI 9700 thermocycler and included the following cycling steps:
Initial denaturing at 98 °C for 5 min followed by 40 cycles of 98 °C ×30 s, 60 °C ×45
s, and 72 °C ×1 min ending with a 72 °C 1× min extension. PCR products from the
extracted DNA sample were run on a 2.0% TAE agarose gel, excised and puriﬁed
using QIAquick Gel Extraction Kit (Cat# 28704, Qiagen, Valencia, CA). PCR
products were quantitated using Quant-iT PicoGreen dsDNA reagent (Cat #
P7589, Invitrogen, Eugene, OR).
To check for proper cluster density and sample normalization, an Illumina
MiSeq single-end 26 bp+ 12 bp index sequencing run was performed using the
MiSeq instrument. The pool was mixed with a PhiX library (Illumina, San Diego
CA) at a ratio of 1:9 in order to increase the entropy of the library. A ﬁnal MiSeq
2 × 150 bp+ 12 bp index sequencing run was performed on the pooled samples.
Reads were ﬁrst ﬁltered to remove the PhiX library reads. All reads mapping to the
Enterobacteria phage PhiX 174 reference genome (GenBank: NC_001422.1) using
the software Bowtie (v1.0.1) were removed from the analysis47. The paired reads
were next merged with the software PEAR (v0.9.5)48. Successfully assembled reads
were analyzed using the QIIME software package (v1.8) with the default quality
control parameters49. Chimeric sequences were identiﬁed and removed from the
dataset using the UCHIME (v6.1) method50. The closed-reference QIIME
protocol was used with the UCLUST method to select operational taxonomic units
(OTUs)51. Sequences with at least 97% identity were clustered together. A
representative sequence from each cluster was used to identify bacterial taxa from
the May 2013 edition of the Greengenes 16S rRNA database (13_8)52,53.
In order to conﬁrm the 16s sequencing data, A. muciniphila levels in fecal
samples were also quantiﬁed using PCR. Quantitative PCR analysis was performed
using an Applied Biosystems 7900 HT Fast Real-Time PCR system and the A.
muciniphila-speciﬁc primer sequences used were AM1 5’CAG CAC GTG AAG
GTG3‘ and AM2 5’CCT TGC GGT TGG CTT CAG3‘. The experimental cycling
conditions were: 40 cycles of 50 °C for 2 min, 95 °C for 10 min, 95 °C for 15 s, 60 °C
for 1 min.
Because the airway microbiome samples (nasal, oral, and BAL) began with
lower biomass starting material, they were subjected to additional quality control
using the negative bronchoscope wash to detect possible contamination. The
predominant 16S rRNA V4 amplicons of pre-procedure bronchoscope control
wash sample (while of low read count) aligned predominantly (84%) to the families
Verrucomicrobiaceae and Enterobacteracaea. These families were assumed to be
contaminants and were subtracted from the analysis of the airway microbiome
samples.
Animal models. Both acute and chronic models of airway inﬂammation were
performed. Female and male wild-type and MyD88−/− BALB/c mice aged
6–8 weeks were obtained from Charles River (Sulzfeld, Germany) and housed at
AO Research Institute Davos for the acute ovalbumin (OVA) and acute house dust
mite (HDM) models. Mice were housed 4–6 animals per cage in individually
ventilated cages in a 12/12 h light/dark cycle with food and water available ad
libitum. All experimental procedures were carried out in accordance with Swiss law
and ethical approval was obtained from Amt fur Lebensmittelsicherheit und
Tiergesundheit, Chur. Female wild-type BALB/c mice for the chronic HDM model
were bred and housed at GlaxoSmithKline (GSK), Stevenage. Animal studies
carried out at GSK were ethically reviewed by the GSK ethics committee and
studies were carried out in accordance with Animals (Scientiﬁc Procedures) Act
1986 and the GSK Policy on the Care, Welfare and Treatment of Animals. All
studies were performed using littermates.
Either ovalbumin (OVA) or house dust mite (HDM) extract were used in acute
models of airway inﬂammation. In the OVA model, mice were sensitized by
intraperitoneal (i.p.) injection of 20 µg of OVA grade VI (Sigma-Aldrich, Buchs,
Switzerland) emulsiﬁed in 500 µg Alum (Pierce, Rockford, IL, USA) in 200 µl sterile
0.9% isotonic Sodium chloride (NaCl) on days 0, 7, and 21, followed by 20 min 1%
OVA grade V (Sigma-Aldrich, Buchs, Switzerland) aerosol exposures on days 26,
27, and 28. Negative control animals received NaCl and alum injections and were
exposed to the OVA aerosolization. Analysis of mice occurred 24 h after the last
aerosol challenge. In the acute HDM model, HDM extract (Greer labs, USA) was
administered intra-nasally (i.n.) on day 0 (1 μg), followed by higher dose i.n.
administrations on days 7, 8, 9, 10, and 11 (10 μg each day). Negative control
animals received saline i.n. on the same days as the positive control animals
received HDM extracts i.n. Animals were euthanized on day 12 for analysis. In
both acute models, A. muciniphila and media control was administered daily (~1 ×
108 cells per dose) by oral gavage, beginning at day −5 until the end of the study. A.
muciniphila was pre-grown in fresh cultures every day in 10 ml aliquots of
anaerobic Mucin v3 media (10% inoculation) at 37 °C. Nitrogen (and boiling) was
used to remove the presence of oxygen from Mucin v3 media. Mucin v3 media
contains peptone (Fluka), yeast extract (Roth), KH2PO4 (Fluka), NaCl (Fluka),
(NH4)SO4 (Acros organics), MgSO4 (Acros organics), CaCl2 (Acros), NaHCO3
(Fluka), D-glucose (Fischer chemical), porcine mucin type II (Sigma), porcine
hemin (Acros organics), L-cysteine (Sigma), and water. For the indicated
experiments, freshly cultured A. muciniphila was heat killed by boiling at 100 °C for
15 min. Cell free supernatants were generated by ﬁltering the culture broth,
following A. muciniphila 24 h culture at 37 °C, through a 0.22 µm syringe ﬁlter
(Sarstedt). Two hundred microliter of the ﬁltered supernatants were orally gavaged
daily to the mice. Fecal and BAL levels of A. muciniphila were determined using
quantitative PCR. Identical primers (i.e., AM1 5’CAG CAC GTG AAG GTG3‘ and
AM2 5’CCT TGC GGT TGG CTT CAG3‘) and cycling conditions were used as
described above for A. muciniphila quantiﬁcation in human samples.
BALs were performed with 1 ml of PBS containing 1× protease inhibitor
cocktail (Roche, Mannheim, Germany). Red blood cells were removed using red
blood cell lysis buffer (Sigma-Aldrich). The total number of leukocytes was counted
with a Neubauer counting chamber. For differential cell counts, cytospin
preparations were ﬁxed and stained with Diff-Quick (Merz & Dade Ag, Dudingen,
Switzerland). Neutrophils, eosinophils, lymphocytes and macrophages were
identiﬁed using standard morphologic criteria and at least 200 cells were counted
per cytospin preparation54. Single cell suspensions were obtained from lung tissue
using GentleMACS (Miltenyi Biotec). Lung-derived single-cell suspensions were
plated at a concentration of 1 × 106 cells/ml in complete RPMI (Sigma-Aldrich)
and were re-stimulated with 50 µg/ml grade VI OVA (Sigma-Aldrich) for 48 h at
37 °C. Culture supernatants were assayed for cytokine levels by Bio-Plex Multiplex
Immunoassay System (Bio-Rad). For lung function measurements, mice were
intubated under anesthesia and airway resistance was assessed using the forced
oscillation technique (FlexiVent system, SCIREQ). Airway resistance was measured
in response to increasing concentrations of methacholine from 0, 0.1, 0.3, 1, 3, 10,
to 30 mg/ml (Sigma-Aldrich)55.
For the chronic HDM models, female BALB/c mice were challenged i.n. with
either sterile saline or 25 µg of HDM extract for 5 days a week, over 3 weeks
(sensitization period, days 1–19). The resulting pulmonary inﬂammation in the
HDM sensitized mice was then allowed to resolve for a period of 2 weeks (days 20
to 33). At the end of the resolution period (day 34), mice were intranasally
challenged with either saline or rechallenged with a high dose of HDM (100 μg).
HDM rechallenge in this model has been shown to induce granulocytic and
lymphocytic inﬁltration into the airways over a 7 day period (days 34 to 40). Mice
were orally gavaged with either mucin v3 media control or A. muciniphila, once a
day, starting on day 20 (post cessation of HDM sensitization). Oral dosing
continued throughout the resolution period and post-HDM rechallenge until day
39. Groups of mice were sacriﬁced at pre-determined time-points during the
resolution phase of the experiment (day 28) and post HDM rechallenge at 4 h (day
34), 24 h (day 35), and day 7 (day 40).
Flow cytometry. Cells present in the broncho-alveolar lavage ﬂuid (BALF) and
lung tissue were quantiﬁed using multi-color ﬂow cytometry. Analysis of myeloid
and lymphoid subsets was performed on a FACSCantoII machine (Becton Dick-
inson) running FACSDiva software version 8. Data analysis was performed using
FlowJo version 7.6.5 (FlowJo LLC, US). Red blood cells of single cell suspensions
containing 1 × 106 cells were lysed using a 1/10 dilution in sterile distilled water of
IO Test 3 solution (Beckman Coulter, UK) for 5 min at room temperature. The
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lysing solution was then washed twice by centrifugation at 370×g for 5 min at 4 oC.
Supernatants were discarded and cell pellets were resuspended in 20 μl Fc−BlockTM
to block non-speciﬁc Fcγ binding sites for 10 min at 4 oC. Without washing off Fc
−BlockTM, cells were stained with 50 μl surface marker antibody cocktails for
10 min at 4 oC in the dark after which cells were washed twice to remove any
unbound antibodies. Cell pellets were then resuspended in 200 μl of FACS buffer
(PBS containing 1% Fetal Calf Serum). For intracellular cytokine staining, freshly
isolated cells were stimulated with PMA/Ionomycin (50 ng/ml and 500 ng/ml,
respectively) for 4 h at 37 °C and 5% CO2 in the presence of Brefeldin (eBioscience,
Vienna, Austria). Cells were permeabilized with reagents from eBioscience
(Vienna, Austria). Data was acquired on a calibrated FACSCantoII ﬂow cytometer
(Becton Dickinson, UK) using ﬂuorochrome compensated protocols. Gating of
intact and single cells (forward scatter Height versus Area) was based on forward
and side scatter characteristics. Leukocyte populations were identiﬁed as CD45+ in
the single cell gate. Cell subsets were identiﬁed as lung resident eosinophils
(CD11c-CD11b+MCHIIloCD24+Siglec-Fint), inﬂammatory eosinophils
(CD11c−CD11b+MHCIIloCD24+Siglec-Fhi), monocytes (CD11c-CD11b+
CD24loMHCIIloCD64loLy6-C+), neutrophils (CD11c−CD11b+MHCIIloCD24+
Ly6-G+), CD8+ T cells (TCRβ+CD8+), B cells (CD45+CD19+), NK cells (CD45+
CD49b+), T cell subsets (TCRβ+CD4+CD44+CD62L−CD183+/− CD196+/−,
IL-4+/−, IFN-γ+/−), or Treg cells (CD3+, CD4+, CD25+, Foxp3+, IL10+). Flow
antibodies to CD45 (30-F11, 1/200 dilution), CD183 (CXCR3–173, 1/200 dilution),
CD196 (140706, 1/200 dilution), TCRβ (H57–597, 1/200 dilution), CD44 (IM7, 1/
200 dilution) and CD62L (MEL-14, 1/200 dilution) were obtained from Becton
Dickinson Biosciences, UK; Biolegend, UK CD11b (M1/70, 1/200 dilution), CD64
(X54–5/7.1, 1/200 dilution), MHCII (M5/114.15–2, 1/200 dilution), CD11c (N418,
1/400 dilution), Ly6-G (1A8, 1/400 dilution), Ly6-C (HK1.4, 1/400 dilution), CD8
(53–6.7, 1/200 dilution), CD49b (DX5, 1/200 dilution), CD3 (145–2C11, 1/100
dilution) and CD4 (RM4–5, 1/200 dilution) were obtained from Biolegend, UK;
eBioscience, Austria CD24 (M1/69, 1/200 dilution), CD25 (PC61.5, 1/200 dilution),
Foxp3 (FJK-16s, 1/50 dilution), IL-10 (JES5–16E3, 1/200 dilution), IL-4 (11B11, 1/
100 dilution), and IFN-γ (XMG1.2, 1/200 dilution) were obtained from
eBioscience, Austria; Siglec−F (ES22–10DB, 1/50 dilution) and CD19 (6D5, 1/30
dilution) were obtained from Miltenyi Biotech, UK.
Statistical analysis. 16S rRNA gene sequencing data analyses were performed
using QIIME or the R language and environment (version 3.3.2). Samples were
rareﬁed to 24,725 reads, which corresponded to the minimum number of aligned
reads to a sample passing quality standards. The Shannon diversity, inverse
Simpson, or Chao1 indices and weighted and unweighted UniFrac distances were
computed at this rarefaction level. Differential abundance for comparisons of taxa
between groups was performed with a one-way ANOVA after correcting for known
covariates, age and gender and a 10% FDR correction for comparisons of taxa,
which were present in at least 10% of all samples for that body site.
Normalization and differential expression analysis of the transcriptomics data
was performed with DESeq2 (version 1.12.4)56 and custom R scripts (version
3.3.2). Differentially expressed transcripts were identiﬁed using a one-way
ANOVA, correcting for age, gender and collection site, followed by Tukey’s
multiple comparison test to compare each group to the non-obese non-asthmatic
group. Signiﬁcance thresholds were set at a p-value equal to or less than 0.01 and at
least a 1.2-fold change difference. Pathway analysis was performed using MetaCore
software (Thomson Reuters, Rochester, NY).
Unless otherwise indicated, data are presented as box-and-whisker plots with
the median value and 10–90 percentile illustrated. For analysis of more than two
groups, statistical signiﬁcance was determined using one-way ANOVA and Tukey’s
multiple comparison test.
Data availability
Microarray data are deposited in National Center for Biotechnology Information (NCBI)
Gene Expression Omnibus (GEO) and are accessible through GEO Series accession
number GSE110551. Study gene sequence data and microbiota sequence data are
deposited in the NCBI Sequence Read Archive under accession number PRJNA434133.
The source data underlying Figs. 1a, 2a, 2b, 4b, 4c, 5b, 5c, 6c–i, 7b, d, e are provided as a
Source Data ﬁle. All other data, resources and reagents are available from the
corresponding author upon reasonable requests.
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